• Completed

NCT01464034: Phase 1/2 - Carfilzomib, Pomalidomide With Dexamethasone in Patients With RRMM

Updated: Sep 27

NCT01464034: Phase 1/2: A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma


KPd

KPd - Myeloma

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma


This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.


Sponsor

Criterium, Inc.


Collaborators

Amgen

Celgene Corporation

 

ClinicalTrials.gov Identifier: NCT01464034

Official Title: A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

First Posted : November 3, 2011

Click here for details on ClinicalTrials.gov

 

Pomalidomide: National Cancer Institute

Pomalidomide: MedlinePlus Drug Information


Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

 

Drug: Carfilzomib

Drug: Pomalidomide

Drug: Dexamethasone

 

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

Blood. 2015 Nov

 

Locations

United States, Georgia

United States, Indiana

United States, New Jersey

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Texas

United States, Washington




Posts Archive